Document is current
Any future updates will be listed below
-
Authors
Lambert, Jordi https://orcid.org/0000-0003-4724-5200
Oc, Sebnem
Worssam, Matthew D. https://orcid.org/0000-0003-4391-5377
Häußler, Daniel https://orcid.org/0000-0003-0658-3262
Solomon, Charles U.
Figg, Nichola L.
Baxter, Ruby https://orcid.org/0009-0009-0926-812X
Imaz, Maria
Taylor, James C. K.
Foote, Kirsty
Finigan, Alison
Mahbubani, Krishnaa T. https://orcid.org/0000-0002-1327-2334
Webb, Tom R. https://orcid.org/0000-0001-5998-8226
Ye, Shu
Bennett, Martin R. https://orcid.org/0000-0002-2565-1825
Krüger, Achim
Spivakov, Mikhail https://orcid.org/0000-0002-0383-3943
Jørgensen, Helle F. https://orcid.org/0000-0002-7909-2977
- License Information
-
More Information
Article History
Received: 26 August 2023
Accepted: 18 April 2024
First Online: 6 June 2024
Competing interests
: M.S. is a shareholder of Enhanc3D Genomics Ltd. H.F.J. is a key opinion leader for Novo Nordisk A/S. The other authors declare no competing interests.
